Until last week, no treatments were approved to keep ovarian cancer away in women who’d responded to an initial round of chemo but didn’t have a BRCA mutation. Now there are two. AstraZeneca and Merck’s Lynparza, in tandem with Roche’s
read moreOnly days after former BARDA chief Rick Bright filed a whistleblower complaint alleging retaliation by the Trump administration, the U.S. Office of the Special Counsel has recommended his temporary reinstatement, the New York Times reports. More: Federal agency finds 'reasonable
read moreGilead Sciences has captured worldwide attention with its COVID-19 antiviral, remdesivir, cleared late last week by the FDA—not all of it welcome. With bad actors targeting companies at the head of the spear in the pandemic response, Gilead may have
read moreApotex is the latest drugmaker to admit to fixing prices on generic drugs. In a deal with the Department of Justice, the company agreed to cooperate with an industrywide probe and pay a $24 million criminal fine. More: Apotex admits
read moreUnlike its first U.K. reimbursement negotiations, Roche’s HER2 antibody-drug conjugate has won quick National Institute for Health and Care Excellence backing for routine NHS coverage to prevent HER2-positive breast cancer from returning after surgery in the so-called adjuvant setting. More:
read more© 1994 - 2026 B.M. Pharmaceuticals